The FreeStyle Libre 3 is one of the most accurate continuous glucose monitors available. In its pivotal clinical trial, the sensor achieved an overall Mean Absolute Relative Difference (MARD) of 7.8%, meaning its readings deviated from lab-grade blood glucose measurements by an average of less than 8%. Lower MARD numbers indicate better accuracy, and anything under 10% is considered highly reliable for making treatment decisions.
What the Clinical Data Shows
MARD is the standard metric for evaluating CGM accuracy. It tells you, on average, how far a sensor’s reading strays from a precise laboratory reference. The Libre 3’s 7.8% overall MARD was measured against a lab analyzer considered the gold standard for glucose measurement, using 6,845 matched data pairs from participants aged 6 and older. In that same study, 93.4% of all sensor readings fell within 20% (or 20 mg/dL) of the reference value.
Adults had slightly better accuracy than children, with a MARD of 7.5% compared to 8.6% for pediatric participants. For the youngest users, children aged 4 and 5, the MARD was 10.0% when measured against fingerstick readings. That’s still within the range considered clinically useful, but parents of younger children should expect a bit more variability.
How It Compares to Dexcom G7
A head-to-head comparison study published in the Journal of Diabetes Science and Technology found the Libre 3 significantly outperformed the Dexcom G7 on accuracy. Against the same lab reference, the Libre 3 had a MARD of 8.9% versus 13.6% for the G7. The percentage of readings falling within the clinically acceptable range of ±20 mg/dL or ±20% was also notably higher for the Libre 3: 91.4% compared to 78.6% for the G7.
The difference was especially pronounced after the initial break-in period. During the first 12 hours of sensor wear, both devices performed similarly (Libre 3 at 14.5% MARD, G7 at 14.4%). But in the 12 to 24 hour window, the Libre 3 settled in much faster, dropping to 10.0% while the G7 remained at 15.1%. The Libre 3 also showed a much smaller overall bias, averaging just 0.6% compared to 9.4% for the G7, meaning the Libre 3 was less likely to consistently read high or low relative to true blood glucose.
When compared against fingerstick readings rather than lab analyzers, both sensors showed higher error rates, but the gap between them widened. The Libre 3 had an 11.4% MARD against capillary blood glucose, while the G7 came in at 18.5%.
Where Accuracy Drops
No CGM perfectly tracks blood glucose in every situation. The Libre 3 measures glucose in interstitial fluid, the thin layer of liquid surrounding cells just beneath your skin, rather than directly in your blood. This creates a natural time lag: when your blood sugar is rising or falling quickly, the sensor reading trails behind reality by several minutes. Studies in children with type 1 diabetes found that MARD roughly doubled during rapid glucose drops greater than 2 mg/dL per minute, climbing from around 10% during stable conditions to nearly 18%.
This lag matters most after meals, during exercise, or when correcting a low. If you feel symptoms of low blood sugar but your sensor shows a normal reading, a fingerstick is a more reliable check in that moment.
Compression Lows
Sleeping on the arm where the sensor is placed can produce false low readings. The pressure reduces fluid flow around the sensor, causing it to report artificially low glucose values. These “compression lows” typically resolve within minutes once you shift positions. If you notice dramatic dips that happen only at night and snap back to normal quickly, pressure on the sensor is the most likely explanation. Wearing the sensor on the arm you don’t sleep on is the simplest fix.
Vitamin C Interference
High doses of vitamin C can cause the Libre 3 to read falsely high. Abbott’s labeling warns that taking more than 500 mg of vitamin C per day may affect sensor readings. The newer Libre 3 Plus has a higher threshold, with interference noted only above 1,000 mg per day. If you take vitamin C supplements, keep this cutoff in mind, especially during cold and flu season when people tend to increase their intake.
First Day Accuracy
Like all CGMs, the Libre 3 is least accurate during its initial hours. The 60-minute warm-up period after insertion is just the beginning. Both the Libre 3 and Dexcom G7 showed elevated error rates in the first 12 hours, with MARD values roughly double what you’d see during the rest of the sensor’s life. By the second half of day one, the Libre 3’s accuracy improved substantially. If a reading looks off during the first day, it’s worth confirming with a fingerstick before making treatment decisions.
Improvement Over Previous Models
The Libre 3 represents a meaningful accuracy upgrade from earlier FreeStyle Libre sensors. Studies comparing the Libre 2’s factory-calibrated algorithm in children found MARD values of 11.3% to 13.7%, noticeably higher than the 8.6% to 9.4% range seen with the Libre 3 in pediatric users. The sensor hardware is also smaller (about the size of two stacked pennies), and it provides continuous real-time glucose streaming rather than requiring you to scan the sensor with your phone.
FDA Classification and Treatment Use
The Libre 3 carries an integrated CGM (iCGM) designation from the FDA, which is the agency’s higher accuracy standard for glucose monitors. This classification means the sensor meets specific performance benchmarks across different glucose ranges and can be used to make insulin dosing decisions without a confirmatory fingerstick. The Libre 3 Plus, a newer variant, is also FDA-approved for use with automated insulin delivery systems, allowing it to communicate directly with compatible insulin pumps to adjust dosing automatically.
In practical terms, most users will find the Libre 3 reliable enough for day-to-day glucose management. The situations where it’s most likely to be off, rapid glucose swings, the first 12 hours of wear, and compression during sleep, are predictable and manageable once you know to watch for them.